Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 497-501

  Kreutzer, Mihaela ^a   Fauti, Tanja ^a   Kaddatz, Kerstin ^a   Seifart, Carola ^a   Neubauer, Andreas ^a   Schweer, Horst ^a   Kömhoff, Martin ^a   Müller Brüsselbach, Sabine ^a   Müller, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cyclooxygenase 2; Non small cell lung cancer

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; PROSTANOID RECEPTOR EP1; PTGER2 PROTEIN, HUMAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CELL STRAIN 3T3; GENETICS; HUMAN; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; EPOPROSTENOL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MASS SPECTROMETRY; MICE; NIH 3T3 CELLS; PROSTAGLANDINS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THROMBOXANE A2;

EID: 34548528621     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.497     Document Type: Article

References (32)

1. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
2. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999. (Pubitemid 30066236)
3. Gupta RA and Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21, 2001. (Pubitemid 33741877)
4. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4: 431-436, 2003. (Pubitemid 38050040)
5. Versteeg HH, van Bergen en Henegouwen PM, van Deventer SJ and Peppelenbosch MP: Cyclooxygenase-dependent signalling: Molecular events and consequences. FEBS Lett 445: 1-5, 1999.
6. Müller R: Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol 130: 429-444, 2004.
7. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M and Taketo MM: Acceleration of intestinal polyposis through prostaglandin receptor ep2 in apc(delta 716) knockout mice. Nat Med 7: 1048-1051, 2001. (Pubitemid 32937386)
8. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S and Taketo MM: Cyclooxygenase 2- and prostaglandin e(2) receptor ep(2)-dependent angiogenesis in apc(delta716) mouse intestinal polyps. Cancer Res 62: 506-511, 2002. (Pubitemid 34110434)
9. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T and Wakabayashi K: Involvement of prostaglandin e receptor subtype ep(4) in colon carcinogenesis. Cancer Res 62: 28-32, 2002. (Pubitemid 34073980)
10. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP and Breyer RM: Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin ep2 receptor. J Clin Invest 111: 727-735, 2003. (Pubitemid 36278591)
11. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S and Majima M: Host prostaglandin e(2)-ep3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197: 221-232, 2003. (Pubitemid 36152316)
12. Kitamura T, Itoh M, Noda T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimura T and Wakabayashi K: Combined effects of prostaglandin e receptor subtype ep1 and subtype ep4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci 94: 618-621, 2003. (Pubitemid 36975017)
13. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M and Ono M: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18: 300-310, 2004. (Pubitemid 38186249)
14. Hatae T, Wada M, Yokoyama C, Shimonishi M and Tanabe T: Prostacyclin-dependent apoptosis mediated by ppar delta. J Biol Chem 276: 46260-46267, 2001.
15. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA and Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62: 734-740, 2002. (Pubitemid 34126948)
16. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD and Coffey RJ: Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63: 1748-1751, 2003. (Pubitemid 36460831)
17. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K and Nukiwa T: Gene transfer of thromboxane a(2) synthase and prostaglandin i(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62: 63-66, 2002. (Pubitemid 34073987)
18. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ and Subbaramaiah K: Inducible prostaglandin e synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7: 2669-2674, 2001. (Pubitemid 32911370)
19. Duperron C and Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in a/j mice. Carcinogenesis 18: 1001-1006, 1997. (Pubitemid 28132346)
20. Rioux N and Castonguay A: Prevention of nnk-induced lung tumorigenesis in a/j mice by acetylsalicylic acid and ns-398. Cancer Res 58: 5354-5360, 1998. (Pubitemid 28551116)
21. Yao R, Rioux N, Castonguay A and You M: Inhibition of cox-2 and induction of apoptosis: Two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 26: 731-742, 2000. (Pubitemid 32044588)
22. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J and Malkinson A: Indomethacin reduces lung adenoma number in a/j mice. Anticancer Res 21: 1749-1755, 2001. (Pubitemid 32728908)
23. Eli Y, Przedecki F, Levin G, Kariv N and Raz A: Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol 61: 565-571, 2001. (Pubitemid 32178490)
24. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, Matsuo K, Sugiura T, Ogawa M and Takahashi T: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, jte-522, and conventional anticancer agents. Clin Cancer Res 8: 2443-2447, 2002. (Pubitemid 34753621)
25. Ermert L, Dierkes C and Ermert M: Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 9: 1604-1610, 2003. (Pubitemid 36554582)
26. Stoner GD, Hallman M and Troxell MC: Lecithin biosynthesis in a clonal line of lung adenoma cells with type ii alveolar cell properties. Exp Mol Pathol 29: 102-114, 1978. (Pubitemid 8405722)
27. Schweer H, Watzer B and Seyberth HW: Determination of seven prostanoids in 1 ml of urine by gas chromatography-negative ion chemical ionization triple stage quadrupole mass spectrometry. J Chromatogr 652: 221-227, 1994. (Pubitemid 24081329)
28. Siegle I, Klein T, Zou MH, Fritz P and Komhoff M: Distribution and cellular localization of prostacyclin synthase in human brain. J Histochem Cytochem 48: 631-641, 2000. (Pubitemid 30233187)
29. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N and Miwa M: Expressions of cyclooxygenase-2 and prostaglandin e-receptors in carcinoma of the gallbladder: Crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8: 1157-1167, 2002. (Pubitemid 35177370)
30. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma cell growth is associated with prostaglandin e2/ep4 receptor-evoked erk activation. J Biol Chem 279: 29797-29804, 2004. (Pubitemid 38915863)
31. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC and Paraskeva C: Increased ep4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66: 3106-3113, 2006.
32. Ma X, Kundu N, Rifat S, Walser T and Fulton AM: Prostaglandin e receptor ep4 antagonism inhibits breast cancer metastasis. Cancer Res 66: 2923-2927, 2006.